Amneal Pharmaceuticals Inc. [NYSE: AMRX] traded at a high on 09/01/22, posting a 7.83 gain after which it closed the day’ session at $2.34. The company report on August 31, 2022 that Amneal Announces Submission of New Drug Application to the U.S. FDA for IPX203 for the Treatment of Parkinson’s Disease.
China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal
Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.
Simply click here and the name & trading symbol are yours.
– IPX203 is a novel, extended-release oral formulation of carbidopa and levodopa that if approved, would offer patients more “Good On” time with fewer doses.
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for IPX203, a novel, oral formulation of carbidopa/levodopa (CD/LD) extended-release capsules for the treatment of Parkinson’s disease (PD).
The results of the trading session contributed to over 2554338 shares changing hands. Over the past one week, the price volatility of Amneal Pharmaceuticals Inc. stands at 6.93% while the volatility over the past one month is 7.59%.
The market cap for AMRX stock reached $718.71 million, with 150.99 million shares outstanding and 118.81 million shares in the current float. Compared to the average trading volume of 939.29K shares, AMRX reached a trading volume of 2554338 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Amneal Pharmaceuticals Inc. [AMRX]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for AMRX shares is $5.80 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on AMRX stock is a recommendation set at 2.40. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
RBC Capital Mkts have made an estimate for Amneal Pharmaceuticals Inc. shares, keeping their opinion on the stock as Sector Perform, with their previous recommendation back on April 07, 2021. While these analysts kept the previous recommendation, Goldman raised their target price from $4 to $6.50. The new note on the price target was released on March 08, 2021, representing the official price target for Amneal Pharmaceuticals Inc. stock. Previously, the target price had yet another raise to $5.50, while Guggenheim analysts kept a Buy rating on AMRX stock. On December 14, 2020, analysts increased their price target for AMRX shares from 4.50 to 6.
The Average True Range (ATR) for Amneal Pharmaceuticals Inc. is set at 0.18, with the Price to Sales ratio for AMRX stock in the period of the last 12 months amounting to 0.34. The Price to Book ratio for the last quarter was 1.26, with the Price to Cash per share for the same quarter was set at 0.30. Price to Free Cash Flow for AMRX in the course of the last twelve months was 5.33 with Quick ratio for the last quarter at 1.00.
How has AMRX stock performed recently?
Amneal Pharmaceuticals Inc. [AMRX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -8.24. With this latest performance, AMRX shares dropped by -35.36% in over the last four-week period, additionally sinking by -43.48% over the last 6 months – not to mention a drop of -56.83% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for AMRX stock in for the last two-week period is set at 34.57, with the RSI for the last a single of trading hit 33.74, and the three-weeks RSI is set at 36.27 for Amneal Pharmaceuticals Inc. [AMRX]. The present Moving Average for the last 50 days of trading for this stock 3.10, while it was recorded at 2.37 for the last single week of trading, and 3.89 for the last 200 days.
Amneal Pharmaceuticals Inc. [AMRX]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Amneal Pharmaceuticals Inc. [AMRX] shares currently have an operating margin of +10.71 and a Gross Margin at +37.81. Amneal Pharmaceuticals Inc.’s Net Margin is presently recorded at +0.51.
Return on Equity for this stock inclined to 3.20, with Return on Assets sitting at 0.27.
Amneal Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.00 and a Current Ratio set at 1.60.
Earnings analysis for Amneal Pharmaceuticals Inc. [AMRX]
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for AMRX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Amneal Pharmaceuticals Inc. go to -12.10%.
Insider trade positions for Amneal Pharmaceuticals Inc. [AMRX]
There are presently around $274 million, or 67.60% of AMRX stock, in the hands of institutional investors. The top three institutional holders of AMRX stocks are: FOSUN INTERNATIONAL LTD with ownership of 21,521,301, which is approximately 0% of the company’s market cap and around 1.60% of the total institutional ownership; TPG GP A, LLC, holding 16,213,367 shares of the stock with an approximate value of $37.94 million in AMRX stocks shares; and TPG GROUP HOLDINGS (SBS) ADVISORS, INC., currently with $37.94 million in AMRX stock with ownership of nearly 0% of the company’s market capitalization.
Positions in Amneal Pharmaceuticals Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 71 institutional holders increased their position in Amneal Pharmaceuticals Inc. [NYSE:AMRX] by around 3,789,587 shares. Additionally, 79 investors decreased positions by around 3,943,038 shares, while 39 investors held positions by with 109,222,251 shares. The mentioned changes placed institutional holdings at 116,954,876 shares, according to the latest SEC report filing. AMRX stock had 18 new institutional investments in for a total of 762,028 shares, while 25 institutional investors sold positions of 956,840 shares during the same period.